Loading company…
NexThera develops protein-based therapies for thrombocytopenia and other conditions.
Founded in 2020, NexThera develops therapies using recombinant proteins and related technologies. Its research includes treatments for thrombocytopenia and age-related macular degeneration, as well as recombinant protein production. Based in Busan, South Korea, the company raised KRW 22.1 billion in Series B funding in September 2026.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in